Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ADH1C | P00326 | 2/20 | 0.36 |
| ▸ | ADH1A | P07327 | 2/20 | 0.36 |
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL200643 | 1.00 | ALDH1A1 (0.37) | ALDH1A1ADH1CADH1AADH1BATM | |
| SCHEMBL555055 | 0.98 | ALDH1A1 (0.40) | ALDH1A1ADH1CADH1AADH1BATM | |
| Hydrochloric Acid SCHEMBL5204062 | 0.98 | ALDH1A1 (0.36) | ALDH1A1ADH1CADH1AADH1BATM | |
| SCHEMBL158232 | 0.98 | ALDH1A1 (0.40) | ALDH1A1ADH1CADH1AADH1BATM | |
| SCHEMBL23275897 | 0.91 | TP53 (0.33) | — | |
| SCHEMBL23275898 | 0.91 | TP53 (0.33) | — | |
| SCHEMBL7269871 | 0.86 | ALDH1A1 (0.33) | ALDH1A1ADH1CADH1AADH1BATM | |
| Proline SCHEMBL1286433 | 0.82 | SCN4A (0.36) | — | |
| SCHEMBL7841830 | 0.81 | ANPEP (0.36) | TSHR | |
| SCHEMBL601670 | 0.78 | FDPS (0.45) | ALDH1A1ADH1CADH1AADH1BTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 308 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260140060-A1 | COLORIMETRIC DETECTION OF A VIRAL INFECTION | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2026-05-21 | — | — | US | disclosed |
| US-20260124281-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | ENTERA BIO LTD. (IL) | 2026-05-07 | — | — | US | disclosed |
| US-20260109870-A1 | PEPTIDE-BASED NON-CRYSTALLINE MATERIALS AND COMPOSITIONS AND PROCESSES FOR OBTAINING SAME | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2026-04-23 | — | — | US | disclosed |
| US-12576191-B2 | Method of inducing cardiomyocytes proliferation and treating heart diseases | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2026-03-17 | — | — | US | disclosed |
| EP-3606615-B1 | METHOD OF STRAIGHTENING HAIR, METHOD FOR MAINTENANCE OF STRAIGHTENED HAIR AND KIT FOR STRAIGHTENING HAIR | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2026-01-07 | — | — | EP | disclosed |
| US-20250369136-A1 | PEPTIDE SELF-ASSEMBLY AS A STRATEGY FOR FACILE IMMOBILIZATION OF ENZYMES AND MICROORGANISMS ON ELECTRODES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2025-12-04 | — | — | US | disclosed |
| US-20250186558-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2025-06-12 | — | — | US | disclosed |
| US-20250186554-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GLUCAGON-LIKE PEPTIDE-1 AND ANALOGS THEREOF | ENTERA BIO LTD. (IL) | 2025-06-12 | — | — | US | disclosed |
| US-20250188150-A1 | PEPTIDES FOR THE TREATMENT OF FIBROSIS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2025-06-12 | — | — | US | disclosed |
| US-20250186555-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GLUCAGON-LIKE PEPTIDE-2 | ENTERA BIO LTD. (IL) | 2025-06-12 | — | — | US | disclosed |
| WO-2004000996-A2 | NUCLEOTIDE SEQUENCES THAT CODE FOR TORSIN GENES, TORSIN PROTEINS, AND METHODS OF USING THE SAME TO TREAT PROTEIN-AGGREGATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2003-12-31 | — | — | WO | disclosed |
| US-20030235823-A1 | Comprises nucleotide sequences coding dystonia protein (TORSIN) for diagnosing and treating nervous system disorders associated with polypeptide aggregation | THE UNIVERSITY OF ALABAMA | 2003-12-25 | — | — | US | disclosed |
| US-20030224013-A1 | Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-04 | — | — | US | disclosed |
| US-20030219455-A1 | Glucanosyl transferase-1 protein useful for immunization against Coccidioides spp. | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-11-27 | — | — | US | disclosed |
| US-20030171289-A1 | Peptides blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof | INSTITUT PASTEUR (FR) | 2003-09-11 | — | — | US | disclosed |
| CN-1427725-A | Casein derived peptides and therapeutic uses thereof | CHAY 13 MEDICAL RES GROUP N V (NL) | 2003-07-02 | — | — | CN | disclosed |
| US-6559126-B2 | Peptides blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof | INSTITUT PASTEUR (FR) | 2003-05-06 | — | — | US | disclosed |
| EP-1268544-A2 | PEPTIDES BLOCKING VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)-MEDIATED ANGIOGENESIS, POLYNUCLEOTIDES ENCODING SAID PEPTIDES AND METHODS OF USE THEREOF | INSTITUT PASTEUR (FR) | 2003-01-02 | — | — | EP | disclosed |
| US-20020068697-A1 | Peptides blocking vascular endothelial growth factor (VEGF) -mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof | INSTITUT PASTEUR (FR) | 2002-06-06 | — | — | US | disclosed |
| WO-2001072829-A2 | PEPTIDES BLOCKING VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)-MEDIATED ANGIOGENESIS, POLYNUCLEOTIDES ENCODING SAID PEPTIDES AND METHODS OF USE THEREOF | INSTITUT PASTEUR (FR) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186555-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GLUCAGON-LIKE PEPTIDE-2 | IAPP, GCG, GLP1R | ALDH1A1 4504/4885ADH1C 1656/4885ADH1A 2461/4885 |
| US-20250186554-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GLUCAGON-LIKE PEPTIDE-1 AND ANALOGS THEREOF | GLP1R, GIPR, GCGR | ALDH1A1 3558/4885ADH1C 1005/4885ADH1A 1285/4885 |
| US-20260124281-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | PTH1R, FGF23, PTMS | ALDH1A1 2763/4885ADH1C 753/4885ADH1A 1516/4885 |
| US-20020068697-A1 | Peptides blocking vascular endothelial growth factor (VEGF) -mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof | KDR, FLT1, FLT4 | ALDH1A1 4722/4885ADH1C 4597/4885ADH1A 4724/4885 |
| US-20250186558-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ASAH2, SLC10A2, FABP2 | ALDH1A1 2002/4885ADH1C 553/4885ADH1A 473/4885 |
| US-20260109870-A1 | PEPTIDE-BASED NON-CRYSTALLINE MATERIALS AND COMPOSITIONS AND PROCESSES FOR OBTAINING SAME | NONO, NGLY1, PTMS | ALDH1A1 4370/4885ADH1C 4646/4885ADH1A 4614/4885 |
| US-12576191-B2 | Method of inducing cardiomyocytes proliferation and treating heart diseases | MYLK2, TNNI3, MYL6 | ALDH1A1 4773/4885ADH1C 4676/4885ADH1A 4823/4885 |
| US-20260140060-A1 | COLORIMETRIC DETECTION OF A VIRAL INFECTION | CTSL, CPA4, ACE2 | ALDH1A1 1754/4885ADH1C 3848/4885ADH1A 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.